|
Gene: LRP2BP |
Gene summary for LRP2BP |
Gene summary. |
Gene information | Species | Human | Gene symbol | LRP2BP | Gene ID | 55805 |
Gene name | LRP2 binding protein | |
Gene Alias | LRP2BP | |
Cytomap | 4q35.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9P2M1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55805 | LRP2BP | HCC1 | Human | Liver | HCC | 1.70e-06 | 9.83e-01 | 0.5336 |
55805 | LRP2BP | HCC2 | Human | Liver | HCC | 1.54e-16 | 1.55e+00 | 0.5341 |
55805 | LRP2BP | HCC5 | Human | Liver | HCC | 2.64e-03 | 6.85e-01 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRP2BP | SNV | Missense_Mutation | c.965N>T | p.His322Leu | p.H322L | Q9P2M1 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
LRP2BP | SNV | Missense_Mutation | rs745629035 | c.722G>A | p.Gly241Glu | p.G241E | Q9P2M1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LRP2BP | SNV | Missense_Mutation | rs770063174 | c.718C>T | p.Arg240Cys | p.R240C | Q9P2M1 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-VS-A94W-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LRP2BP | SNV | Missense_Mutation | c.901N>A | p.Phe301Ile | p.F301I | Q9P2M1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
LRP2BP | SNV | Missense_Mutation | rs765686066 | c.844G>A | p.Ala282Thr | p.A282T | Q9P2M1 | protein_coding | deleterious(0) | benign(0.37) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRP2BP | SNV | Missense_Mutation | rs780750023 | c.808N>A | p.Ala270Thr | p.A270T | Q9P2M1 | protein_coding | tolerated(0.67) | benign(0.019) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LRP2BP | SNV | Missense_Mutation | novel | c.487N>A | p.Ala163Thr | p.A163T | Q9P2M1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LRP2BP | SNV | Missense_Mutation | c.515N>T | p.Ser172Ile | p.S172I | Q9P2M1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
LRP2BP | SNV | Missense_Mutation | c.361N>T | p.Leu121Phe | p.L121F | Q9P2M1 | protein_coding | deleterious(0.04) | benign(0.073) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
LRP2BP | SNV | Missense_Mutation | rs778371816 | c.998N>T | p.Ala333Val | p.A333V | Q9P2M1 | protein_coding | tolerated(0.33) | benign(0) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |